Business Context and Reporting Period
This Form 8-K Current Report from Harmony Biosciences Holdings, Inc. (HRMY) covers events occurring on March 31, 2026, and April 2, 2026. The filing primarily addresses significant changes to the Company's executive leadership and Board of Directors composition.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
Executive Leadership Changes
- Appointment of COO: Peter Anastasiou was appointed Senior Executive Vice President and Chief Operating Officer, effective April 2, 2026.
- Resignation of Director: Mr. Anastasiou resigned from the Board of Directors and all committees effective April 2, 2026, to assume the executive role. The resignation was not due to any disagreement with the Company.
Board of Directors Changes
- New Director Appointment: Troy Ignelzi was appointed as a Class III director effective April 2, 2026, filling the vacancy left by Mr. Anastasiou. He will serve on the Audit and Compensation Committees starting May 14, 2026.
- Director Departure: Antonio Gracias notified the Board on March 31, 2026, that he would not stand for re-election. His term ends at the 2026 Annual Meeting.
Compensation and Employment Terms
Mr. Anastasiou's new employment agreement includes the following key terms:
- Base Salary: $600,000 annually.
- Target Bonus: 55% of annual base salary, contingent on performance objectives.
- Equity Grant: Stock option award with a grant date fair value of $3,700,000. Vesting is 25% on the first anniversary and 75% quarterly thereafter over four years.
- Severance Provisions: Includes 12 months of base salary and healthcare coverage upon termination without cause or for good reason. Change in control triggers full accelerated vesting of the stock option and pro-rata bonus payments.
Investor Verification Checklist
- Verify the impact of the new COO's commercial background (Lundbeck, Capsida) on the Company's strategic direction.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for specific performance metrics tied to the bonus structure.
- Confirm the timeline for the 2026 Annual Meeting to finalize the Board composition changes.
- Assess the financial impact of the $3.7 million equity grant on future dilution and stock-based compensation expenses.